FloraWorks Latest News

The SupplySide Supplement Journal recently published a feature spotlighting groundbreaking clinical research on cannabinoids, including FloraWorks' innovative work with TruCBN™. This publication marks a significant step in bridging the gap between anecdotal claims and scientific validation, highlighting the importance of rigorous research in advancing the wellness industry.

New research highlights Cannabinol (CBN) as a promising, non-intoxicating solution for restorative sleep, addressing the root causes of sleep issues rather than masking symptoms. FloraWorks’ clinical study and findings from Neuropsychopharmacology validate CBN's efficacy in improving sleep quality and duration, offering a science-backed alternative to traditional sleep aids.

Learn how CBN provides unique opportunities for B2B product innovation in the sleep supplement market

In a groundbreaking development for the cannabinoid industry, FloraWorks has announced the peer-reviewed publication of a pivotal study on their proprietary product, TruCBN™.

Our CEO, Alleh Lindquist, recently shared some exciting developments on The Dime podcast, highlighting how FloraWorks is leading the charge in reshaping the wellness industry with cannabinoid-based products.

Learn about CBN's journey to prominence, its impact on the cannabinoid market, and why it's become the go-to ingredient for natural sleep solutions.

FloraWorks is excited to welcome Dr. Matthew Roberts as the new Chief Operating Officer (COO). Dr. Roberts will oversee operations, supply chain management, production, quality assurance, and regulatory affairs.

In a groundbreaking development, the revolutionary TruCBN™ study will be presented at the prestigious SLEEP meeting, the premier annual meeting for sleep medicine and research professionals.

In an unprecedented collaborative effort, FloraWorks and The Salk Institute have unveiled groundbreaking research elucidating the neuroprotective effects of cannabinoids on aging neuronal cells.

In recent years, the interest in cannabinoids—compounds found in the cannabis plant—has surged, not just among researchers but also within the general populace seeking alternative therapies for various health issues.

In a notable development within the biotech industry, FloraWorks, a leading company in cannabinoid research, is set to make a significant presentation at the upcoming Global Cannabinoid Research Society Conference.

In the rapidly evolving world of scientific research and technological development, staying ahead of the curve is not just an advantage; it's a necessity. This is where FloraWorks' latest innovation, Paragon, comes into play.